These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 10793559)

  • 41. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
    Zinzani PL; Barbieri E; Visani G; Gherlinzoni F; Perini F; Neri S; Bendandi M; Ammendolia I; Salvucci M; Babini L
    Haematologica; 1994; 79(6):508-12. PubMed ID: 7534744
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer.
    Lalisang RI; Wils JA; Nortier HW; Burghouts JT; Hupperets PS; Erdkamp FL; Schouten HC; Blijham GH
    J Clin Oncol; 1997 Apr; 15(4):1367-76. PubMed ID: 9193328
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
    Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
    Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy.
    Avilés A; Díaz-Maqueo JC; Talavera A; Nambo MJ; García EL
    Leuk Lymphoma; 1994 Sep; 15(1-2):153-7. PubMed ID: 7532056
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Short-term rhG-CSF priming before chemotherapy does mobilize blood progenitors but does not prevent chemotherapy induced myelotoxicity: a randomized study of patients with non-Hodgkin's lymphomas.
    Hansen PB; Johnsen HE; Ralfkiaer E; Jensen L; Gaarsdal E; Hansen NE
    Leuk Lymphoma; 1995 Nov; 19(5-6):453-60. PubMed ID: 8590846
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized comparison of mobilization kinetics of circulating CD34+ cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma. The lenograstim/Lymphoma Study Group.
    Itoh K; Ohtsu T; Sasaki Y; Ogura M; Morishima Y; Kasai M; Chou T; Yoshida K; Ohno T; Mizorogi F; Uike N; Sai T; Taniwaki M; Ikeda S; Tobinai K
    Leuk Lymphoma; 2000 Aug; 38(5-6):521-32. PubMed ID: 10953973
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
    Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
    Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low-dose epirubicin in combination with cyclophosphamide, vinblastine and prednisone (mini-CEOP) for the treatment of aggressive non-Hodgkin's lymphoma in elderly patients.
    Veneri D; Zanetti F; Franchini M; Krampera M; Pizzolo G
    Haematologica; 2002 Nov; 87(11):ELT43. PubMed ID: 12414364
    [No Abstract]   [Full Text] [Related]  

  • 49. [Usefulness of COP-BLAM therapy with concomitant G-CSF in elderly patients with non-Hodgkin's lymphoma in comparison with patients not given G-CSF].
    Niitsu N; Umeda M
    Nihon Ronen Igakkai Zasshi; 1995 Jun; 32(6):410-5. PubMed ID: 7563935
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkins lymphoma.
    McBride NC; Cavenagh JD; Ward MC; Grant I; Schey S; Gray A; Hughes A; Mills MJ; Cervi P; Newland AC; Kelsey SM
    Leuk Lymphoma; 2001 Jun; 42(1-2):89-98. PubMed ID: 11699226
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
    Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S
    J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
    De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
    Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
    Hashino S; Morioka M; Irie T; Shiroshita N; Kawamura T; Suzuki S; Iwasaki H; Umehara S; Kakinoki Y; Kurosawa M; Kahata K; Izumiyama K; Kobayashi H; Onozawa M; Takahata M; Fujisawa F; Kondo T; Asaka M
    Int J Lab Hematol; 2008 Aug; 30(4):292-9. PubMed ID: 18665826
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 55. VEDex (vincristine, epirubicin dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma.
    El Helw LM; Lorigan PC; Robinson MH; Coleman RE; Hancock BW
    Int J Oncol; 2000 Apr; 16(4):777-82. PubMed ID: 10717248
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
    Smith GM; Child JA; Cullen MH; Bailey NP; Woodruffe CM; Fletcher J; Earl H; Barnard D
    Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma.
    Nair R; Ramakrishnan G; Nair NN; Saikia TK; Parikh PM; Joshi SR; Soman CS; Mukhadan M; Dinshaw KT; Advani SH
    Cancer; 1998 Jun; 82(11):2282-8. PubMed ID: 9610711
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of non-Hodgkin's lymphoma in the elderly. The Italian studies.
    Salvagno L; Errante D; Bianco A; Palmisano V; Ballerini F; Boccalon M; Aversa S; Monfardini S
    Tumori; 2002; 88(1 Suppl 1):S20-5. PubMed ID: 11989915
    [No Abstract]   [Full Text] [Related]  

  • 59. Infusional chemotherapy for non-Hodgkin's lymphoma.
    Molldrem J; Wilson WH
    Cancer Invest; 1997; 15(5):465-74. PubMed ID: 9316629
    [No Abstract]   [Full Text] [Related]  

  • 60. Epirubicin in non-Hodgkin's lymphomas.
    Lopez M; Perno CF; Di Lauro L; Papaldo P; Ganzina F; Di Pietro N
    Am J Clin Oncol; 1985 Apr; 8(2):151-3. PubMed ID: 3869431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.